750 related articles for article (PubMed ID: 16026693)
1. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
Magrath I; Shanta V; Advani S; Adde M; Arya LS; Banavali S; Bhargava M; Bhatia K; Gutiérrez M; Liewehr D; Pai S; Sagar TG; Venzon D; Raina V
Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
4. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
[TBL] [Abstract][Full Text] [Related]
6. [Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?].
Schrøder H; Kjeldstad M; Boesen AM; Nielsen OJ; Schmidt KG; Johnsen HE; Gregersen H; Gustafsson G
Ugeskr Laeger; 2006 Jun; 168(26-32):2554-8. PubMed ID: 16824410
[TBL] [Abstract][Full Text] [Related]
7. [Influence of age on treatment results in children and adolescents with Hodgkin's disease].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():40-4. PubMed ID: 15686044
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
[TBL] [Abstract][Full Text] [Related]
9. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome of adolescents with acute lymphoblastic leukemia.
Irken G; Oren H; Gülen H; Duman M; Uçar C; Atabay B; Yilmaz S; Uysal K; Cevik N
Ann Hematol; 2002 Nov; 81(11):641-5. PubMed ID: 12454702
[TBL] [Abstract][Full Text] [Related]
12. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
Boissel N; Auclerc MF; Lhéritier V; Perel Y; Thomas X; Leblanc T; Rousselot P; Cayuela JM; Gabert J; Fegueux N; Piguet C; Huguet-Rigal F; Berthou C; Boiron JM; Pautas C; Michel G; Fière D; Leverger G; Dombret H; Baruchel A
J Clin Oncol; 2003 Mar; 21(5):774-80. PubMed ID: 12610173
[TBL] [Abstract][Full Text] [Related]
13. Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience.
Thomas X; Olteanu N; Charrin C; Lhéritier V; Magaud JP; Fiere D
Am J Hematol; 2001 Jun; 67(2):73-83. PubMed ID: 11343378
[TBL] [Abstract][Full Text] [Related]
14. High-risk childhood acute lymphoblastic leukemia in China: factors influencing the treatment and outcome.
Luo XQ; Ke ZY; Huang LB; Guan XQ; Zhang YC; Zhang XL
Pediatr Blood Cancer; 2009 Feb; 52(2):191-5. PubMed ID: 18989886
[TBL] [Abstract][Full Text] [Related]
15. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB
J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603
[TBL] [Abstract][Full Text] [Related]
16. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
17. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
18. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE).
Donadieu J; Auclerc MF; Baruchel A; Perel Y; Bordigoni P; Landman-Parker J; Leblanc T; Cornu G; Sommelet D; Leverger G; Schaison G; Hill C;
Br J Cancer; 2000 Dec; 83(12):1617-22. PubMed ID: 11104555
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
20. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
